共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
Alessandro Beneduce Giuseppe Ferrante Alfonso Ielasi Carlo A. Pivato Mauro Chiarito Alberto Cappelletti Luca Baldetti Valeria Magni Eugenio Prati Stefania Falcone Adele Pierri Stefano De Martini Matteo Montorfano Rosario Parisi David Rutigliano Nicola Locuratolo Angelo Anzuini Maurizio Tespili Alberto Margonato Alberto Benassi Carlo Briguori Bernhard Reimers Franco Fabbiocchi Antonio Bartorelli Antonio Colombo Cosmo Godino 《Catheterization and cardiovascular interventions》2020,96(2):255-265
3.
Yaling Han MD FSCAI Quanmin Jing MD Xuezhi Chen MD Shouli Wang MD Yingyan Ma MD Haiwei Liu MD Bo Luan MD Geng Wang MD Yi Li MD Zulu Wang MD Dongmei Wang MD Bo Xu MD Runlin Gao MD FACC 《Catheterization and cardiovascular interventions》2008,72(2):177-183
Background: The residual drug carriers on drug‐eluting stents (DES) surfaces are considered to be one of the most significant reasons causing late thrombosis. There is no documented data currently available on the safety/benefit profile beyond 6 months of EXCEL stent, a novel sirolimus‐eluting stent with biodegradable polymer coating, in treating patients with coronary artery disease (CHD). Objective: To evaluate the long‐term efficacy and safety of EXCEL stent on treating CHD patients. Methods: Between February and March 2006, a consecutive cohort of complex patients treated with the EXCEL stent was prospectively enrolled in this single‐center registry. Antiplatelet protocol was 6‐month dual antiplatelet therapy with clopidogrel and aspirin followed by aspirin alone indefinitely. The primary outcome was major adverse cardiac events (MACE) at 12 months. Secondary outcomes included in‐segment and in‐stent late lumen loss and binary restenosis rate measured by quantitative coronary angiography (QCA) analysis at 8 months postindex PCI procedure. Results: A total of 100 patients with 153 lesions were included in this analysis. Most lesions (83.0%) were classified as complex (B2/C). At 12 months, four patients (4.0%) experienced MACE, which were four target‐lesion revascularizations due to in‐stent restenosis (ISR). All patients received follow‐up up to 24 ± 0.4 months and no cardiac death, MI, and in‐stent thrombosis occurred during the 6 months of dual antiplatelet therapy or the subsequent 15 months of aspirin treatment alone. QCA analysis of 112 lesions from 75 patients showed 3.6% (4/112) in‐stent lesion restenosis, 5.4% (6/112) in‐segment lesion restenosis, 0.12 ± 0.34 mm in‐stent late lumen loss, and 0.08 ± 0.35 mm in‐segment late lumen loss. Conclusions: In this single‐center experience with complex patients and lesions, the EXCELTM stent implantation with 6‐month dual antiplatelet treatment proved to markedly reduce the incidence of 24‐month ISR and MACE. These preliminary findings require further validation by large scale, randomized trials. © 2008 Wiley‐Liss, Inc. 相似文献
4.
Elisabetta Moscarella MD Alfonso Ielasi MD Alessandro Beneduce MD Giuseppe Ferrante MD PhD Andrea Carlo Pivato MD Mauro Chiarito MD Alberto Cappelletti MD Giulia Perfetti MD Valeria Magni MD Eugenio Prati MD Stefania Falcone MD Adele Pierri MD Stefano De Martini MD Matteo Montorfano MD Rosario Parisi MD David Rutigliano MD Nicola Locuratolo MD Angelo Anzuini MD Paolo Calabrò MD PhD Maurizio Tespili MD PhD Alberto Margonato MD PhD Alberto Benassi MD Carlo Briguori MD PhD Franco Fabbiocchi MD Bernhard Reimers MD Antonio Bartorelli MD PhD Antonio Colombo MD Cosmo Godino MD 《Catheterization and cardiovascular interventions》2019,94(7):972-979
5.
6.
7.
Efficacy and safety of a second‐generation biodegradable polymer sirolimus‐eluting stent: One‐year results of the CREDIT 2 trial 下载免费PDF全文
Kai Xu Yaling Han Bo Xu Yuejin Yang Geng Wang Hui Li Yong Sun Ling Tao Haichang Wang Zuyi Yuan Huiliang Liu Jinghua Liu Yongping Jia Genshan Ma Guosheng Fu Xiaodong Li Shuren Li Shouli Wang Kui Pu the CREDIT Investigators 《Cardiovascular therapeutics》2018,36(3)
8.
Andrs Iiguez Bernard Chevalier Gert Richardt Antoinette Neylon Victor A. Jimnez Ran Kornowski Didier Carrie Raul Moreno Emanuele Barbato Antoni Serra‐Pearanda Vincenzo Guiducci Mariano Valds‐Chvarri Junji Yajima William Wijns Shigeru Saito 《Catheterization and cardiovascular interventions》2020,95(2):175-184
9.
One‐year clinical outcomes after sirolimus‐eluting coronary stent implantation in diabetics enrolled in the worldwide e‐SELECT registry 下载免费PDF全文
Antonio L. Bartorelli MD Gabriele Egidy Assenza MD Alexandre Abizaid MD Adrian Banning MD Vladimír Džavík MD Stephen Ellis MD Runlin Gao MD David Holmes MD Myung Ho Jeong MD Victor Legrand MD Franz‐Josef Neumann MD Christian Spaulding MD Stephen G. Worthley MD Philip Urban MD for the e‐SELECT Investigators 《Catheterization and cardiovascular interventions》2016,87(1):52-62
10.
11.
Deborah N. Kalkman Laura S. Kerkmeijer Pier Woudstra Ian B. A. Menown Harry Suryapranata Peter den Heijer Andrs Iiguez Arnoud W. J. van 't Hof Andrejs Erglis Karin E. Arkenbout Philippe Muller Karel T. Koch Jan G. Tijssen Marcel A. M. Beijk Robbert J. de Winter 《Catheterization and cardiovascular interventions》2019,94(3):342-347
12.
Angiographic predictors of 2‐year stent thrombosis in patients receiving drug‐eluting stents: Insights from the ADAPT‐DES study 下载免费PDF全文
Philippe Généreux MD Björn Redfors MD PhD Bernhard Witzenbichler MD Akiko Maehara MD Mayank Yadav MD Giora Weisz MD Dominic P. Francese MPH Rupa Parvataneni MS Sorin J. Brener MD Roxana Mehran MD Ajay J. Kirtane MD SM Gregg W. Stone MD 《Catheterization and cardiovascular interventions》2017,89(1):26-35
13.
A propensity score‐matched comparison of biodegradable polymer vs second‐generation durable polymer drug‐eluting stents in a real‐world population 下载免费PDF全文
Ying Jiao Zhao Monica Teng Ai Leng Khoo Rajiv Ananthakrishna Tiong Cheng Yeo Boon Peng Lim Joshua P. Loh Mark Y. Chan 《Cardiovascular therapeutics》2018,36(2)
14.
Procedural resources utilization and clinical outcomes with bioresorbable everolimus‐eluting scaffolds and Pt‐Cr everolimus‐eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial 下载免费PDF全文
Jose M. de la Torre Hernandez MD PhD Tamara Garcia Camarero MD Dae‐Hyun Lee MD Fermin Sainz Laso MD Gabriela Veiga Fernandez MD Tania Pino MD Silvia Rubio MD Pablo Legarra MD Jorge R. Valdivia MD Javier Zueco Gil MD 《Catheterization and cardiovascular interventions》2017,90(2):E25-E30
15.
Two‐year clinical outcomes of the NOBORI biolimus‐eluting stents versus XIENCE/PROMUS everolimus‐eluting stents in small vessel disease 下载免费PDF全文
Hiroyuki Jinnouchi MD Shoichi Kuramitsu MD Tomohiro Shinozaki MPH Takashi Hiromasa MD Yohei Kobayashi MD Takashi Morinaga MD Kyohei Yamaji MD Yoshimitsu Soga MD Shinichi Shirai MD Kenji Ando MD 《Catheterization and cardiovascular interventions》2016,88(5):E132-E138
16.
17.
Anna Plitt Bimmer E. Claessen Samantha Sartori Usman Baber Jaya Chandrasekhar Melissa Aquino Pooja Vijay Sherif Elsayed Jason C. Kovacic Joseph Sweeny Nitin Barman Pedro Moreno Prakash Krishnan Antonia Demopoulos George Dangas Annapoorna S. Kini Roxana Mehran Samin K. Sharma 《Catheterization and cardiovascular interventions》2020,96(3):558-564
18.
19.
Ravi K. Ramana DO Adam Ronan MD Kevin Cohoon DO David Homan MD Jessica Sutherland MD Lowell Steen MD Jayson Liu MD Henry Loeb MD Bruce E. Lewis MD 《Catheterization and cardiovascular interventions》2008,71(7):886-893
Objective : To evaluate the long‐term clinical outcomes of patients undergoing percutaneous coronary intervention for saphenous vein graft (SVG) disease. Specifically, we compared clinical endpoints of patients who received sirolimus‐eluting stents (SES) versus bare‐metal stents (BMS) for SVG disease. Background : A recent small randomized‐controlled trial (RCT) reported increased mortality with the use of SES in SVG disease. Methods : We retrospectively identified patients who underwent SES placement for a SVG lesion(s) at our institutions over a 4‐year period. The procedural and medical records were reviewed to identify predetermined clinical outcomes. Results : 318 patients who underwent SES placement for a SVG lesion were identified. 7 patients were lost to follow‐up. 141/311 patients (45%) received SES, while 170/311 (55%) received BMS. At a mean follow‐up of 34 months, there was a reduction in target lesion revascularization (TLR) (7% vs. 14%, P = 0.07) without an increased risk of mortality (6% vs. 12%, P = 0.06) in patients who received SES compared to patients who received BMS. When compared to the recent RCT's SES patients at long‐term follow‐up, our SES patients had significantly less mortality; rates of myocardial infarction, TLR, target vessel revascularization, and major adverse cardiac events; and were more likely to be taking dual antiplatelet and statin medications. Conclusion : Our results support that SES used in SVG lesions result in a reduction in TLR without an increased risk of mortality, and therefore may be an equally safe and feasible technique for revascularization with excellent long‐term clinical outcomes. These patients may benefit from prolonged dual antiplatelet and statin medication regimens. © 2008 Wiley‐Liss, Inc. 相似文献
20.
Real‐life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) 下载免费PDF全文
Giovanna Sarno Bo Lagerqvist Göran Olivecrona Christoph Varenhorst Mikael Danielewicz Kristina Hambraeus Daniel Lindholm Truls Råmunddal Nils Witt Stefan James 《Catheterization and cardiovascular interventions》2017,90(6):881-887